373 related articles for article (PubMed ID: 28737885)
1. Classics in Chemical Neuroscience: Memantine.
Alam S; Lingenfelter KS; Bender AM; Lindsley CW
ACS Chem Neurosci; 2017 Sep; 8(9):1823-1829. PubMed ID: 28737885
[TBL] [Abstract][Full Text] [Related]
2. Rationale for combination therapy with galantamine and memantine in Alzheimer's disease.
Grossberg GT; Edwards KR; Zhao Q
J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):17S-26S. PubMed ID: 16809811
[TBL] [Abstract][Full Text] [Related]
3. The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism.
Lipton SA
Curr Alzheimer Res; 2005 Apr; 2(2):155-65. PubMed ID: 15974913
[TBL] [Abstract][Full Text] [Related]
4. NMDA receptor antagonists. A new therapeutic approach for Alzheimer's disease.
Farlow MR
Geriatrics; 2004 Jun; 59(6):22-7. PubMed ID: 15224791
[TBL] [Abstract][Full Text] [Related]
5. [Glutamate-related excitotoxicity neuroprotection with memantine, an uncompetitive antagonist of NMDA-glutamate receptor, in Alzheimer's disease and vascular dementia].
Tanović A; Alfaro V
Rev Neurol; 2006 May 16-31; 42(10):607-16. PubMed ID: 16703529
[TBL] [Abstract][Full Text] [Related]
6. Alzheimer's disease and the glutamate NMDA receptor.
Doraiswamy PM
Psychopharmacol Bull; 2003; 37(2):41-9. PubMed ID: 14566213
[TBL] [Abstract][Full Text] [Related]
7. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders.
Lipton SA
J Alzheimers Dis; 2004 Dec; 6(6 Suppl):S61-74. PubMed ID: 15665416
[TBL] [Abstract][Full Text] [Related]
8. [Memantine: from the original brand to generics].
Titova NV
Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(10):136-143. PubMed ID: 29171502
[TBL] [Abstract][Full Text] [Related]
9. Management of moderate to severe Alzheimer's disease: focus on memantine.
Dominguez E; Chin TY; Chen CP; Wu TY
Taiwan J Obstet Gynecol; 2011 Dec; 50(4):415-23. PubMed ID: 22212311
[TBL] [Abstract][Full Text] [Related]
10. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
Tariot PN; Farlow MR; Grossberg GT; Graham SM; McDonald S; Gergel I;
JAMA; 2004 Jan; 291(3):317-24. PubMed ID: 14734594
[TBL] [Abstract][Full Text] [Related]
11. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease.
Rogawski MA; Wenk GL
CNS Drug Rev; 2003; 9(3):275-308. PubMed ID: 14530799
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of action of memantine.
Johnson JW; Kotermanski SE
Curr Opin Pharmacol; 2006 Feb; 6(1):61-7. PubMed ID: 16368266
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of memantine in moderate-to-severe Alzheimer disease: the evidence to date.
Bullock R
Alzheimer Dis Assoc Disord; 2006; 20(1):23-9. PubMed ID: 16493232
[TBL] [Abstract][Full Text] [Related]
14. Pharmacology of acetylcholinesterase inhibitors and N-methyl-D-aspartate receptors for combination therapy in the treatment of Alzheimer's disease.
Geerts H; Grossberg GT
J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):8S-16S. PubMed ID: 16809810
[TBL] [Abstract][Full Text] [Related]
15. Memantine: targeting glutamate excitotoxicity in Alzheimer's disease and other dementias.
Molinuevo JL; Lladó A; Rami L
Am J Alzheimers Dis Other Demen; 2005; 20(2):77-85. PubMed ID: 15844753
[TBL] [Abstract][Full Text] [Related]
16. [Memantine: a therapeutic drug for Alzheimer's disease and the comparison with MK-801].
Kato T
Nihon Yakurigaku Zasshi; 2004 Sep; 124(3):145-51. PubMed ID: 15333987
[TBL] [Abstract][Full Text] [Related]
17. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse.
Parsons CG; Stöffler A; Danysz W
Neuropharmacology; 2007 Nov; 53(6):699-723. PubMed ID: 17904591
[TBL] [Abstract][Full Text] [Related]
18. Memantine in the treatment of mild-to-moderate Alzheimer's disease.
Cosman KM; Boyle LL; Porsteinsson AP
Expert Opin Pharmacother; 2007 Feb; 8(2):203-14. PubMed ID: 17257090
[TBL] [Abstract][Full Text] [Related]
19. Neuropathologic changes in Alzheimer's disease: potential targets for treatment.
Wenk GL
J Clin Psychiatry; 2006; 67 Suppl 3():3-7; quiz 23. PubMed ID: 16649845
[TBL] [Abstract][Full Text] [Related]
20. Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation.
Lipton SA
Curr Drug Targets; 2007 May; 8(5):621-32. PubMed ID: 17504105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
